top of page

ASGCT 2026: Coave Therapeutics has a unique conjugation approach to delivering AAV to the right place in the body - at ASGCT they presented on the platform and lead internal program for wet AMD

  • May 13
  • 1 min read

CEO Rodolphe Clerval describes the platform, which they can partner using a company's existing AAV assets or with Coave's new OneAAV universal capsid. Plus, why he thinks Coave's wet AMD program, which will be administered at the point of care, could be best in class.





Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page